Patent · US Active

Pharmaceutical composition for treating ulcerative colitis

US10183022B2 · kind B2 · utility

0Cited by

0References

11Claims

0Family size

Assignee

EA PHARMA CO., LTD. · JP

Inventors

Shunsuke Kageyama · Tokyo, JP
Yoshiki Goda · Tokyo, JP
Toshihiko Sugiura · Tokyo, JP

Key dates

Filing date	Mar 28, 2017
Grant date	Jan 22, 2019
Priority date	—
Expiry date	Mar 28, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P1/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is a pharmaceutical composition for treating ulcerative colitis, comprising a compound represented by a formula (1) or a pharmaceutically acceptable salt thereof, wherein the compound or the pharmaceutically acceptable salt is administered in an amount of 600 mg or more per day to an ulcerative colitis patient.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.